JP2008524236A5 - - Google Patents

Download PDF

Info

Publication number
JP2008524236A5
JP2008524236A5 JP2007546887A JP2007546887A JP2008524236A5 JP 2008524236 A5 JP2008524236 A5 JP 2008524236A5 JP 2007546887 A JP2007546887 A JP 2007546887A JP 2007546887 A JP2007546887 A JP 2007546887A JP 2008524236 A5 JP2008524236 A5 JP 2008524236A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
halogen
hydroxyphenyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007546887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/045375 external-priority patent/WO2006065968A2/en
Publication of JP2008524236A publication Critical patent/JP2008524236A/ja
Publication of JP2008524236A5 publication Critical patent/JP2008524236A5/ja
Pending legal-status Critical Current

Links

JP2007546887A 2004-12-17 2005-12-15 エストロゲンβアゴニストについての新規用途 Pending JP2008524236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17
PCT/US2005/045375 WO2006065968A2 (en) 2004-12-17 2005-12-15 The uses of estrogen beta agonists to treat cognitive diseases

Publications (2)

Publication Number Publication Date
JP2008524236A JP2008524236A (ja) 2008-07-10
JP2008524236A5 true JP2008524236A5 (cg-RX-API-DMAC7.html) 2009-02-05

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546887A Pending JP2008524236A (ja) 2004-12-17 2005-12-15 エストロゲンβアゴニストについての新規用途

Country Status (20)

Country Link
US (1) US20060135574A1 (cg-RX-API-DMAC7.html)
EP (1) EP1824478A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008524236A (cg-RX-API-DMAC7.html)
KR (1) KR20070086329A (cg-RX-API-DMAC7.html)
CN (1) CN101321524A (cg-RX-API-DMAC7.html)
AR (1) AR051844A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005316561A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519111A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590258A1 (cg-RX-API-DMAC7.html)
GT (1) GT200500370A (cg-RX-API-DMAC7.html)
IL (1) IL183604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007007347A (cg-RX-API-DMAC7.html)
NI (1) NI200700152A (cg-RX-API-DMAC7.html)
NO (1) NO20072658L (cg-RX-API-DMAC7.html)
PA (1) PA8656601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20061113A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007120254A (cg-RX-API-DMAC7.html)
TW (1) TW200637545A (cg-RX-API-DMAC7.html)
WO (1) WO2006065968A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705103B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
US10758496B2 (en) * 2014-09-02 2020-09-01 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2018183800A1 (en) * 2017-03-30 2018-10-04 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
DE60116109T2 (de) * 2001-11-07 2006-09-07 Schering Ag In vitro Screening nach Liganden des Östrogenrezeptors
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
WO2004026290A1 (en) * 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
JP2008505095A (ja) * 2004-07-01 2008-02-21 ワイス エストロゲンリガンドとしての四環式化合物

Similar Documents

Publication Publication Date Title
Uthayathas Versatile effects of sildenafil: recent pharmacological applications
Forrer et al. Experimental physiological studies with lysergic acid diethylamide (LSD-25)
Yanagisawa Functions and dysfunctions of the basal ganglia in humans
Koshino et al. Enhancement of rolandic mu-rhythm by pattern vision
JP7506046B2 (ja) 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩
CA2433858A1 (en) Purine derivatives as purinergic receptor antagonists
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
JP2003517437A (ja) インビボでシチジンレベルを上昇させ、シチジン依存性のヒト疾患を治療するための方法
Sechi et al. Restless legs syndrome and periodic limb movements after ischemic stroke in the right lenticulostriate region
JP2022549335A5 (cg-RX-API-DMAC7.html)
RS67956B1 (sr) Troriluzol za upotrebu u lečenju spinocerebelarne ataksije 3 (sca3)
DE69936994T2 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
CA2509251A1 (en) Method of treating cognitive decline due to sleep deprivation and stress
Ezenwanne Current concepts in the neurophysiologic basis of sleep; a review
Calne et al. Dopamine agonists in Parkinson’s disease
WO2012125400A1 (en) Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases
DE69923338T2 (de) Kombinationstherapie zur behandlung von hepatitis b infektionen
RU2097034C1 (ru) Фармацевтический препарат антиалкогольного и ноотропного действия
RU2007120254A (ru) Новые способы применения агонистов эстрогена бета
Thompson The dawn of the yawn: is yawning a warning? Linking neurological disorders
CN109251155A (zh) α-氨基酰胺衍生物及其用途
JP2005532339A (ja) cGMP刺激性化合物
Rahm Fundamental principles of pharmacology
AU2010295445B2 (en) Role of N-2 hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury
US20070265238A1 (en) Method for accelerating reentrainment of a circadian rhythm